An open-label, randomized, Phase III Study of Nivolumab in Combination with Ipilimumab or with Standard Chemotherapy versus Standard Chemotherapy in Patients with previously untreated inoperable or metastatic Urothelial Carcinoma (CheckMate-901) - AB 59/17 of the AUO First-line Therapy for untreated, non-resectable or metastatic Urothelial Carcinoma

被引：0
|
作者：
Rexer, H. [1 ]
Retz, M. [2 ]
Waller, C. [3 ]
机构：
[1] AUO Geschaftsstelle, Seestr 11, D-17252 Schwarz, Germany
[2] Deutsch Krebsgesell eV, Arbeitsgemeinschaft Urol Onkol, Kuno Fischer Str 8, D-14057 Berlin, Germany
[3] Uniklinikum Freiburg, Innere Med Klin 1, Hugstetter Str 55, D-79106 Freiburg, Germany
来源：
UROLOGE | 2018年 / 57卷 / 07期
关键词：
D O I：
10.1007/s00120-018-0698-z
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：880 / 881
页数：2
相关论文
共 50 条
  • [1] First-line Treatment of untreated, non-resectable or metastatic Urothelial Carcinoma: An open, randomized, Phase III Study of Nivolumab in Combination with Ipilimumab or Standard Chemotherapy versus Standard-Chemotherapy in Patients with previously untreated inoperable or metastatic Urothelial Carcinoma (CheckMate-901) - AB 59/17 of the AUO
    Rexer, H.
    Retz, M.
    Waller, C.
    AKTUELLE UROLOGIE, 2019, 50 (01) : 20 - 21
  • [2] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients with previously untreated unresectable or metastatic urothelial carcinoma (CheckMate 901)
    Waller, C. F.
    Galsky, M. D.
    Powles, T.
    van der Heijden, M. S.
    Li, S.
    Hennicken, D.
    Sonpavde, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 324 - 325
  • [3] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
    Galsky, Matt D.
    Powles, Thomas
    Li, Shengting
    Hennicken, Delphine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [4] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
    Galsky, Matt D.
    Powles, Thomas
    Li, Shengting
    Hennicken, Delphine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Sternberg, Cora
    McDermott, David F.
    Larkin, James M. G.
    Ravaud, Alain
    Rini, Brian I.
    Sharma, Padmanee
    Bhagavatheeswaran, Prabhu
    Gagnier, Paul
    Motzer, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Therapy of untreated local advanced or metastatic Renal Cell Carcinoma Phase III, Randomized, Open-label Study of Nivolumab combined with Ipilimumab versus Sunitinib-Monotherapy in Subjects with previously untreated, local advanced or metastatic Renal Cell Carcinoma (CheckMate 214-AN36/15 of the AUO)
    Rexer, H.
    UROLOGE, 2015, 54 (10): : 1443 - 1445
  • [7] A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)
    Powles, T. B.
    van der Heijden, M. S.
    Castellano Gauna, D.
    Loriot, Y.
    Galsky, M. D.
    Petrylak, D. P.
    Ogawa, O.
    Park, S. H.
    Necchi, A.
    Lee, J-L.
    De Giorgi, U.
    Boegemann, M.
    Bamias, A.
    Fay, A. P.
    Duran, I.
    Angra, N.
    Gupta, A. K.
    He, P.
    Levin, W.
    Bellmunt, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S550 - S551
  • [8] A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated metastatic renal cell carcinoma
    Hammers, H.
    Sternberg, C.
    Mcdermott, D. F.
    Larkin, J.
    Ravaud, A.
    Rini, B.
    Sharma, P.
    Bhagavatheeswaran, P.
    Gagnier, P.
    Motzer, R.
    BJU INTERNATIONAL, 2014, 114 : 9 - 9
  • [9] First-line treatment for locally advanced or metastatic urothelial carcinoma: a randomized controlled phase III study comparing pembrolizumab with and without platinum-based combination chemotherapy and chemotherapy alone in patients with advanced or metastatic urothelial carcinoma (Keynote-361) AB 54/16 of AUO
    Rexer, H.
    Ohlmann, C. -H.
    Retz, M.
    AKTUELLE UROLOGIE, 2018, 49 (01) : 21 - 22
  • [10] First-line Therapy for locally advanced or metastatic Urothelial Carcinoma A randomized, controlled Phase-III-Trial comparing Pembrolizumab with or without platinum-based Combination Chemotherapy and Chemotherapy only in Patients with advanced or metastatic Urothelial Carcinoma (Keynote-361-AB 54/16 of the AUO)
    Rexer, H.
    Ohlmann, C. -H.
    Retz, M.
    UROLOGE, 2017, 56 (05): : 659 - 661
12345